These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21324692)

  • 1. Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
    Narayan S; Carlson EM; Cheng H; Condon K; Du H; Eckley S; Hu Y; Jiang Y; Kumar V; Lewis BM; Saxton P; Schuck E; Seletsky BM; Tendyke K; Zhang H; Zheng W; Littlefield BA; Towle MJ; Yu MJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1634-8. PubMed ID: 21324692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
    Narayan S; Carlson EM; Cheng H; Du H; Hu Y; Jiang Y; Lewis BM; Seletsky BM; Tendyke K; Zhang H; Zheng W; Littlefield BA; Towle MJ; Yu MJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1630-3. PubMed ID: 21324686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model.
    Narayan S; Carlson EM; Cheng H; Condon K; Du H; Eckley S; Hu Y; Jiang Y; Kumar V; Lewis BM; Saxton P; Schuck E; Seletsky BM; Tendyke K; Zhang H; Zheng W; Littlefield BA; Towle MJ; Yu MJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1639-43. PubMed ID: 21324687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin shows high concentration and long retention in xenograft tumor tissues.
    Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
    Koyama N; Tokunaga T; Ogasawara W; Murakami M; Yamashita Y
    Nihon Yakurigaku Zasshi; 2011 Nov; 138(5):209-17. PubMed ID: 22075465
    [No Abstract]   [Full Text] [Related]  

  • 7. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
    Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
    Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.
    Laughney AM; Kim E; Sprachman MM; Miller MA; Kohler RH; Yang KS; Orth JD; Mitchison TJ; Weissleder R
    Sci Transl Med; 2014 Nov; 6(261):261ra152. PubMed ID: 25378644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
    Goto W; Kashiwagi S; Asano Y; Takada K; Takahashi K; Fujita H; Takashima T; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
    Anticancer Res; 2019 Aug; 39(8):4031-4041. PubMed ID: 31366485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
    Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
    Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.
    Miki S; Imamichi S; Fujimori H; Tomiyama A; Fujimoto K; Satomi K; Matsushita Y; Matsuzaki S; Takahashi M; Ishikawa E; Yamamoto T; Matsumura A; Mukasa A; Nishikawa R; Masutomi K; Narita Y; Masutani M; Ichimura K
    Cancer Sci; 2018 Jul; 109(7):2275-2285. PubMed ID: 29758120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.
    Thara E; Gitlitz BJ
    Future Oncol; 2014 Oct; 10(12):1913-24. PubMed ID: 25386810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
    Devriese LA; Witteveen PO; Marchetti S; Mergui-Roelvink M; Reyderman L; Wanders J; Jenner A; Edwards G; Beijnen JH; Voest EE; Schellens JH
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):823-32. PubMed ID: 23010853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
    O'Sullivan Coyne G; Walsh J; Kelly CM
    Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin mesylate for the treatment of late-stage breast cancer.
    Gourmelon C; Frenel JS; Campone M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
    Cortes J; Lorca R
    Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
    Lim HI; Yamamoto J; Inubushi S; Nishino H; Tashiro Y; Sugisawa N; Han Q; Sun YU; Choi HJ; Nam SJ; Kim MB; Lee JS; Hozumi C; Bouvet M; Singh SR; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2481-2485. PubMed ID: 32366392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?
    Aftimos P; Awada A
    Adv Ther; 2011 Nov; 28(11):973-85. PubMed ID: 22020735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.